Mitochondrial Agents for Bipolar Disorder

Círia Pereira, Victor Chavarria, João Vian, Melanie Maree Ashton, Michael Berk, Wolfgang Marx, Olivia May Dean

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)
18 Downloads (Pure)

Abstract

Background: Bipolar disorder is a chronic and often debilitating illness. Current treatment options (both pharmaco- and psychotherapy) have shown efficacy, but for many leave a shortfall in recovery. Advances in the understanding of the pathophysiology of bipolar disorder suggest that interventions that target mitochondrial dysfunction may provide a therapeutic benefit.

Methods: This review explores the current and growing theoretical rationale as well as existing preclinical and clinical data for those therapies aiming to target the mitochondrion in bipolar disorder. A Clinicaltrials.gov and ANZCTR search was conducted for complete and ongoing trials on mitochondrial agents used in psychiatric disorders. A PubMed search was also conducted for literature published between January 1981 and July 2017. Systematic reviews, randomized controlled trials, observational studies, case series, and animal studies with an emphasis on agents affecting mitochondrial function and its role in bipolar disorder were included. The search was augmented by manually searching the references of key papers and related literature. The results were presented as a narrative review.

Results: Mitochondrial agents offer new horizons in mood disorder treatment. While some negative effects have been reported, most compounds are overall well tolerated and have generally benign side-effect profiles.

Conclusions: The study of neuroinflammation, neurodegeneration, and mitochondrial function has contributed the understanding of bipolar disorder's pathophysiology. Agents targeting these pathways could be a potential therapeutic strategy. Future directions include identification of novel candidate mitochondrial modulators as well as rigorous and well-powered clinical trials.

Original languageEnglish
Pages (from-to)550-569
Number of pages20
JournalInternational Journal of Neuropsychopharmacology
Volume21
Issue number6
DOIs
Publication statusPublished - 1 Jun 2018
Externally publishedYes

Fingerprint

Bipolar Disorder
Therapeutics
Mood Disorders
PubMed
Psychotherapy
Observational Studies
Psychiatry
Mitochondria
Randomized Controlled Trials
Clinical Trials
Drug Therapy

Cite this

Pereira, C., Chavarria, V., Vian, J., Ashton, M. M., Berk, M., Marx, W., & Dean, O. M. (2018). Mitochondrial Agents for Bipolar Disorder. International Journal of Neuropsychopharmacology, 21(6), 550-569. https://doi.org/10.1093/ijnp/pyy018
Pereira, Círia ; Chavarria, Victor ; Vian, João ; Ashton, Melanie Maree ; Berk, Michael ; Marx, Wolfgang ; Dean, Olivia May. / Mitochondrial Agents for Bipolar Disorder. In: International Journal of Neuropsychopharmacology. 2018 ; Vol. 21, No. 6. pp. 550-569.
@article{34c4ad81eb014cf09b215042538034df,
title = "Mitochondrial Agents for Bipolar Disorder",
abstract = "Background: Bipolar disorder is a chronic and often debilitating illness. Current treatment options (both pharmaco- and psychotherapy) have shown efficacy, but for many leave a shortfall in recovery. Advances in the understanding of the pathophysiology of bipolar disorder suggest that interventions that target mitochondrial dysfunction may provide a therapeutic benefit.Methods: This review explores the current and growing theoretical rationale as well as existing preclinical and clinical data for those therapies aiming to target the mitochondrion in bipolar disorder. A Clinicaltrials.gov and ANZCTR search was conducted for complete and ongoing trials on mitochondrial agents used in psychiatric disorders. A PubMed search was also conducted for literature published between January 1981 and July 2017. Systematic reviews, randomized controlled trials, observational studies, case series, and animal studies with an emphasis on agents affecting mitochondrial function and its role in bipolar disorder were included. The search was augmented by manually searching the references of key papers and related literature. The results were presented as a narrative review.Results: Mitochondrial agents offer new horizons in mood disorder treatment. While some negative effects have been reported, most compounds are overall well tolerated and have generally benign side-effect profiles.Conclusions: The study of neuroinflammation, neurodegeneration, and mitochondrial function has contributed the understanding of bipolar disorder's pathophysiology. Agents targeting these pathways could be a potential therapeutic strategy. Future directions include identification of novel candidate mitochondrial modulators as well as rigorous and well-powered clinical trials.",
author = "C{\'i}ria Pereira and Victor Chavarria and Jo{\~a}o Vian and Ashton, {Melanie Maree} and Michael Berk and Wolfgang Marx and Dean, {Olivia May}",
year = "2018",
month = "6",
day = "1",
doi = "10.1093/ijnp/pyy018",
language = "English",
volume = "21",
pages = "550--569",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "6",

}

Pereira, C, Chavarria, V, Vian, J, Ashton, MM, Berk, M, Marx, W & Dean, OM 2018, 'Mitochondrial Agents for Bipolar Disorder' International Journal of Neuropsychopharmacology, vol. 21, no. 6, pp. 550-569. https://doi.org/10.1093/ijnp/pyy018

Mitochondrial Agents for Bipolar Disorder. / Pereira, Círia; Chavarria, Victor; Vian, João; Ashton, Melanie Maree; Berk, Michael; Marx, Wolfgang; Dean, Olivia May.

In: International Journal of Neuropsychopharmacology, Vol. 21, No. 6, 01.06.2018, p. 550-569.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Mitochondrial Agents for Bipolar Disorder

AU - Pereira, Círia

AU - Chavarria, Victor

AU - Vian, João

AU - Ashton, Melanie Maree

AU - Berk, Michael

AU - Marx, Wolfgang

AU - Dean, Olivia May

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background: Bipolar disorder is a chronic and often debilitating illness. Current treatment options (both pharmaco- and psychotherapy) have shown efficacy, but for many leave a shortfall in recovery. Advances in the understanding of the pathophysiology of bipolar disorder suggest that interventions that target mitochondrial dysfunction may provide a therapeutic benefit.Methods: This review explores the current and growing theoretical rationale as well as existing preclinical and clinical data for those therapies aiming to target the mitochondrion in bipolar disorder. A Clinicaltrials.gov and ANZCTR search was conducted for complete and ongoing trials on mitochondrial agents used in psychiatric disorders. A PubMed search was also conducted for literature published between January 1981 and July 2017. Systematic reviews, randomized controlled trials, observational studies, case series, and animal studies with an emphasis on agents affecting mitochondrial function and its role in bipolar disorder were included. The search was augmented by manually searching the references of key papers and related literature. The results were presented as a narrative review.Results: Mitochondrial agents offer new horizons in mood disorder treatment. While some negative effects have been reported, most compounds are overall well tolerated and have generally benign side-effect profiles.Conclusions: The study of neuroinflammation, neurodegeneration, and mitochondrial function has contributed the understanding of bipolar disorder's pathophysiology. Agents targeting these pathways could be a potential therapeutic strategy. Future directions include identification of novel candidate mitochondrial modulators as well as rigorous and well-powered clinical trials.

AB - Background: Bipolar disorder is a chronic and often debilitating illness. Current treatment options (both pharmaco- and psychotherapy) have shown efficacy, but for many leave a shortfall in recovery. Advances in the understanding of the pathophysiology of bipolar disorder suggest that interventions that target mitochondrial dysfunction may provide a therapeutic benefit.Methods: This review explores the current and growing theoretical rationale as well as existing preclinical and clinical data for those therapies aiming to target the mitochondrion in bipolar disorder. A Clinicaltrials.gov and ANZCTR search was conducted for complete and ongoing trials on mitochondrial agents used in psychiatric disorders. A PubMed search was also conducted for literature published between January 1981 and July 2017. Systematic reviews, randomized controlled trials, observational studies, case series, and animal studies with an emphasis on agents affecting mitochondrial function and its role in bipolar disorder were included. The search was augmented by manually searching the references of key papers and related literature. The results were presented as a narrative review.Results: Mitochondrial agents offer new horizons in mood disorder treatment. While some negative effects have been reported, most compounds are overall well tolerated and have generally benign side-effect profiles.Conclusions: The study of neuroinflammation, neurodegeneration, and mitochondrial function has contributed the understanding of bipolar disorder's pathophysiology. Agents targeting these pathways could be a potential therapeutic strategy. Future directions include identification of novel candidate mitochondrial modulators as well as rigorous and well-powered clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=85061530059&partnerID=8YFLogxK

U2 - 10.1093/ijnp/pyy018

DO - 10.1093/ijnp/pyy018

M3 - Article

VL - 21

SP - 550

EP - 569

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 6

ER -

Pereira C, Chavarria V, Vian J, Ashton MM, Berk M, Marx W et al. Mitochondrial Agents for Bipolar Disorder. International Journal of Neuropsychopharmacology. 2018 Jun 1;21(6):550-569. https://doi.org/10.1093/ijnp/pyy018